Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $15.0800 (-2.96%) ($14.9100 - $15.3900) on Tue. Jun. 30, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.48% (three month average) | RSI | 72 | Latest Price | $15.0800(-2.96%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.6% a day on average for past five trading days. | Weekly Trend | FOLD advances 13.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) IWO(51%) XBI(50%) IWM(47%) IWC(45%) | Factors Impacting FOLD price | FOLD will decline at least -2.24% in a week (0% probabilities). VIXM(-29%) VXX(-14%) UUP(-12%) IYT(-5%) XLC(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.24% (StdDev 4.48%) | Hourly BBV | 0 () | Intraday Trend | -1.6% | | | |
|
5 Day Moving Average | $15.3(-1.44%) | 10 Day Moving Average | $15.02(0.4%) | 20 Day Moving Average | $13.61(10.8%) | To recent high | -3.9% | To recent low | 70.2% | Market Cap | $3.894b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |